Researchers at UC Irvine issue a warning that GLP-1RAs may be dangerous for children Source: UC Irvine School of Medicine Irvine, CA, August 28, 2023 A team of clinicians, exercise scientists, pharmaceutical scholars, ethicists and behavioral experts at the University of California, Irvine, outlined their concerns that the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) to treat childhood obesity and type 2 diabetes may have unintended and adverse consequences for childrens health
These meds have historically run upward of $1,000 without insurance (and coverage is still limited)though both Eli Lilly (Zepbound) and Novo Nordisk (Wegovy) have recently cut that price in half, to $499 a month, for folks without coverage who opt in to direct-pay programs with the drugmakers
For use by qualified professionals in a controlled laboratory environment only.
Therefore, discovering a small molecule GLP-1RA that could be orally administered is a current but extremely challenging research hotspot